|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Anti-MDA5 antibody-positive DM patients showed high T1-IFN signatures in serum and affected skin.
|
30541137 |
2019 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
We aimed to investigate the clinical value of checking serum chitinase-3-like-1 protein (YKL-40) levels in anti-MDA5 antibody-positive dermatomyositis (anti-MDA5<sup>+</sup>DM) patients.
|
30739212 |
2019 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
This study aimed to investigate the clinical significance of Krebs von den Lungen-6 (KL-6) serum levels in patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5<sup>+</sup> DM) having interstitial lung disease (ILD), especially in the amyopathic DM phenotype.
|
31301087 |
2019 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
We report the case of an anti-MDA5 Ab-positive DM patient who had developed RPILD despite intensive treatments; she was treated successfully by a short-term plasma exchange (PE).
|
29642214 |
2018 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Anti-MDA5 antibodies have been strongly associated with rapidly progressive interstitial lung disease (RP-ILD) in dermatomyositis (DM) patients, especially in the clinically amyopathic subset (CADM).
|
29417209 |
2018 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
There has been no case report of an anti-MDA5 Ab-positive DM patient with the recurrence of ILD after 7 years of long-term remission.
|
29952940 |
2018 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
Anti-MDA5 were originally identified in a clinically-defined subset of DM patients whose disease was expressed predominately in the skin for unusually long periods of time without accompanying muscle weakness [i.e., "clinically-amyopathic DM" (CADM)] and were at risk for acute, rapidly-progressive form of interstitial lung disease (ILD).
|
28480196 |
2017 |
|
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Enterovirus infections have been linked to diabetes development, and a polymorphism (A946T) in the innate immune sensor recognizing enterovirus RNA, interferon-induced with helicase C domain 1/melanoma differentiation-associated protein 5, predisposes to disease.
|
27482829 |
2016 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
BEFREE |
INS,UBASH3A, and IFIH1 were significantly associated with progression from IA to diabetes (HR=1.65, 1.44, and 1.47, respectively, all p ≤ 0.04), while PTPN22 and IL27 showed borderline association with progression from IA to diabetes.
|
25075402 |
2014 |
|
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The greatest diabetes discrimination was obtained by the sum of risk alleles for eight genes (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL and ERBB3) in the HLA-risk children.
|
22932816 |
2012 |
|
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Islet autoantibody-positive children with the IFIH1 rs2111485 GG genotype had a faster progression to diabetes (31% within 5 years) than children with the type 1 diabetes protective GA or AA genotypes (11% within 5 years; P = 0.006).
|
21270278 |
2011 |
|
Diabetes Mellitus
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Rare IFIH1 alleles have been shown to be protective against diabetes, and their carriage correlates with lower production of this helicase and its functional disruption.
|
20121398 |
2010 |
|
Diabetes Mellitus
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|